Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cyclacel Pharmaceuti 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 USA

www.cyclacel.com Employees: 8 P: 908-517-7330 F: 866-271-3466

Description:

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

Key Statistics

Overview:

Market Capitalization, $K 1,996
Enterprise Value, $K -1,384
Shares Outstanding, K 6,287
Annual Sales, $ 420 K
Annual Net Income, $ -22,560 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -1,960 K
EBIT, $ -15,540 K
EBITDA, $ -15,510 K
60-Month Beta 0.38
% of Insider Shareholders 8.00%
% of Institutional Shareholders 23.58%
Float, K 5,784
% Float 92.00%
Short Volume Ratio 0.22

Growth:

1-Year Return -90.05%
3-Year Return -99.47%
5-Year Return -99.81%
5-Year Revenue Growth 180.00%
5-Year Earnings Growth 85.61%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 11/12/24
Next Earnings Date 11/11/24
Earnings Per Share ttm -9.40
EPS Growth vs. Prev Qtr 75.00%
EPS Growth vs. Prev Year 97.55%
Annual Dividend Yield 0.00%
Most Recent Dividend 0.150 on 07/13/16
Next Ex-Dividends Date 07/13/16
Dividend Payable Date 08/01/16
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 12/18/23

CYCC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -1,901.11%
Return-on-Assets % -188.23%
Profit Margin % -5,371.43%
Debt/Equity 0.00
Price/Sales 4.95
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.45
Interest Coverage -2.80

CYCC Dividends

Date Value
07/13/16 $0.1500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar